Clinical Trials Logo

Recurrent Melanoma clinical trials

View clinical trials related to Recurrent Melanoma.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT02236546 Terminated - Stage IV Melanoma Clinical Trials

FDG-PET in Advanced Melanoma

Start date: May 2012
Phase: N/A
Study type: Interventional

This clinical trial studies how well FDG-PET/CT measures early response in patients with stage III-IV melanoma who are receiving chemotherapy. Positron emission tomography (PET)/computed tomography (CT) uses a metabolic imaging radiotracer, [18F]fluorodeoxyglucose (FDG), which selectively accumulates in tumors. FDG-PET/CT of advanced melanoma before, during, and after treatment may improve methods for predicting which patients may benefit from therapy.

NCT ID: NCT02203604 Terminated - Stage IV Melanoma Clinical Trials

High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery

Start date: November 26, 2014
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well high-dose aldesleukin and ipilimumab works in treating patients with stage III-IV melanoma that cannot be removed by surgery. Biological therapies, such as aldesleukin, may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Monoclonal antibodies, such as ipilimumab, interfere with the ability of tumor cells to grow and spread. Giving high-dose aldesleukin together with ipilimumab may work better in treating patients with melanoma.

NCT ID: NCT01970527 Terminated - Recurrent Melanoma Clinical Trials

Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma

Start date: March 2014
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well stereotactic body radiotherapy and ipilimumab work in treating patients with stage IV melanoma. Stereotactic body radiotherapy (SBRT) may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Monoclonal antibodies, such as ipilimumab, target certain cells to interfere with the ability of tumor cells to grow and spread. Giving SBRT with ipilimumab may kill more tumor cells.

NCT ID: NCT01835184 Terminated - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery

Start date: May 2013
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of cabozantinib-s-malate when given together with vemurafenib in treating patients with solid tumors or melanoma that is metastatic or that cannot be removed by surgery. Cabozantinib-s-malate and vemurafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01769222 Terminated - Clinical trials for Recurrent Mantle Cell Lymphoma

Ipilimumab and Local Radiation for Selected Solid Tumors

Start date: February 2013
Phase: Phase 1
Study type: Interventional

This pilot phase 1-2 trial studies the side effects and best of dose ipilimumab when given together with local radiation therapy and to see how well it works in treating patients with recurrent melanoma, non-Hodgkin lymphoma, colon, or rectal cancer. Monoclonal antibodies, such as ipilimumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Radiation therapy uses high energy x rays to kill cancer cells. Giving monoclonal antibody therapy together with radiation therapy may be an effective treatment for melanoma, non-Hodgkin lymphoma, colon, or rectal cancer. - The phase 1 component ("safety") of this study is ipilimumab 25 mg monotherapy. - The phase 2 component ("treatment-escalation") of this study is ipilimumab 25 mg plus radiation combination therapy.

NCT ID: NCT01744171 Terminated - Recurrent Melanoma Clinical Trials

Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma

Start date: March 26, 2013
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with stage III-IV melanoma that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Vaccines made from peptides or antigens may help the body build an effective immune response to kill tumor cells.

NCT ID: NCT01701037 Terminated - Recurrent Melanoma Clinical Trials

Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery

Start date: January 2013
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well giving dabrafenib alone and in combination with trametinib before surgery works in treating patients with advanced melanoma that can be removed by surgery. Studying samples of tumor tissue in the laboratory from patients receiving dabrafenib and trametinib may help doctors learn more about the effects of these drugs on cells and help identify biomarkers that determine which patients will respond to these drugs best.

NCT ID: NCT01533948 Terminated - Stage IV Melanoma Clinical Trials

Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery

Start date: January 2012
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well axitinib works in treating patients with melanoma that has spread to other places in the body or cannot be removed by surgery. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01519427 Terminated - Stage IV Melanoma Clinical Trials

Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib

Start date: January 2012
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well selumetinib and Akt inhibitor MK2206 works in treating patients with stage III or stage IV melanoma who failed prior therapy with vemurafenib or dabrafenib. Selumetinib and Akt inhibitor MK2206 stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet know whether giving selumetinib and Akt inhibitor MK2206 together is an effective treatment for advanced melanoma.

NCT ID: NCT01316692 Terminated - Stage IV Melanoma Clinical Trials

Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma

Start date: October 2011
Phase: Phase 2
Study type: Interventional

RATIONALE: Aurora A kinase inhibitor MLN8237 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well Aurora A kinase inhibitor MLN8237 works in treating patients with unresectable stage III-IV melanoma Funding Source - FDA OOPD